Rennaz

Researchers are evaluating the effectiveness, safety, and tolerability of camizestrant combined with ribociclib in patients with advanced ER-positive, HER2-negative breast cancer who have not received any prior systemic treatment for their advanced disease. This Phase IIIb global, multicenter, single-arm study aims to provide insight into this combination therapy as a first-line treatment option. Participants will receive daily oral tablets of camizestrant 75 mg and ribociclib 600 mg at standard doses continuously until they choose to stop treatment or it is discontinued for any reason. Approximately 150 participants will be enrolled and treated within this trial. During the study, participants will be monitored for treatment effectiveness using time to next treatment, time to discontinuation, and progression-free survival over a two-year period. Safety will be assessed by tracking adverse events, including any severe toxicities within the first six months. Participants will undergo regular assessments related to organ function and performance status throughout the treatment period, which may last until discontinuation.

This research aims to evaluate the effects of improved teamwork between hospital pharmacists and community pharmacists during the hospital discharge process. It focuses on adult patients admitted to an internal medicine ward who take seven or more medications and are discharged to their home. The study investigates whether this enhanced collaboration can reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions compared to usual care. The study has two groups one receiving standard care where physicians handle medication reconciliation and patients receive prescriptions directly, and an intervention group where hospital pharmacists actively support medication management. This includes contacting community pharmacies before discharge to order specific medications, performing medication reconciliation with hospital physicians, sending discharge prescriptions to community pharmacies, and providing additional patient and prescription information. Participants will continue their usual routine by going to their regular community pharmacy after discharge. Researchers will assess the number of drug-related issues seven days post-discharge, patient satisfaction at the same time, community pharmacists satisfaction over six months, and hospital readmission rates within 30 days. The study involves monitoring and collecting information through these measures to understand the impact of the pharmacist collaboration on medication safety and patient care.

Researchers are evaluating the effect of preoperative oral immunonutrition IN on reducing post-operative complications in patients undergoing cystectomy, a surgery to remove the bladder. This multicenter randomized controlled trial aims to assess whether IN can improve outcomes like infections after surgery and to develop a method to identify patients who would benefit most from this nutrition. The study addresses the high complication rates associated with cystectomy and the role of malnutrition as a risk factor. Participants are randomly assigned to one of two groups one receives seven days of oral immunonutrition before surgery, and the other follows standard care without IN. The immunonutrition supplement, Oral Impact, is taken three times daily for seven days before the operation. The trial compares these approaches to see if preoperative IN reduces complications and improves immune response. During the study, researchers will monitor infectious complications within 30 days after surgery as the primary outcome. Secondary outcomes include overall complication rates at 30 and 90 days, mortality rates, complication-free survival, and treatment compliance. Participants will be assessed through clinical evaluations and compliance tracking from 30 days before surgery through hospital admission. The total participation duration varies depending on surgery timing and follow-up assessments.